Ticker Details
Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).
IPO Date:	February 6, 2007
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.94B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.54 | 2.78%
Avg Daily Range (30 D):	$12.24 | 2.32%
Avg Daily Range (90 D):	$10.19 | 1.98%

Institutional Daily Volume
Avg Daily Volume:	.22M
Avg Daily Volume (30 D):	.29M
Avg Daily Volume (90 D):	.26M

Trade Size
Avg Trade Size (Sh.):	40
Avg Trade Size (Sh.) (30 D):	22
Avg Trade Size (Sh.) (90 D):	22

Institutional Trades
Total Institutional Trades:	2,701
Avg Institutional Trade:	$8.04M
Avg Institutional Trade (30 D):	$16.68M
Avg Institutional Trade (90 D):	$23.35M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$8.71M
Avg Closing Trade (30 D):	$20.48M
Avg Closing Trade (90 D):	$25.66M
Avg Closing Volume:	34.47K

News

Jun 16, 2026 @ 7:30 AM 3 Under-the-Radar Stocks to Buy and Hold for a Dec... Source: Prosper Junior Bakiny

Apr 22, 2026 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: Na

Apr 1, 2026 @ 12:49 AM The $578 Billion Regenerative Medicine Market Has ... Source: Usa News Group

Mar 25, 2026 @ 9:24 PM Prediction: 2 Stocks That Will Be Worth More Than ... Source: Prosper Junior Bakiny

Mar 21, 2026 @ 11:19 PM This New $193 Million Bet Targets a Biotech With $... Source: Jonathan Ponciano

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-11.28	$-1.99	$-3.25
Diluted EPS	$-11.28	$-1.99	$-3.25
Revenue	$1.28B	$364.25M	$311.34M
Gross Profit
Net Income / Loss	$-325.1M	$-57.94M	$-94.39M
Operating Income / Loss	$-322.62M	$-56.31M	$-92.72M
Cost of Revenue
Net Cash Flow	$100.3M	$60.64M	$27.09M
PE Ratio

Splits
Jul 25, 2016	1:35